Innovating Works

PARAGON NOVEL VACCINE

Financiado
Paragon Novel Vaccine (PNV) an effective protection against all serotypes of fiv...
Paragon Novel Vaccine (PNV) an effective protection against all serotypes of five deadly bacteria to eradicate Antimicrobial Resistance (AMR) Immunethep has developed, patented (WO/2015/189422), and successfully undergone preclinical trials for a new breakthrough vaccine (PNV-Paragon Novel Vaccine). It protects against bacterial infections caused by 5 different bacteria... ver más
30/06/2025
IMMUNETHEP
7M€
Presupuesto del proyecto: 7M€
ver más
Líder del proyecto
IMMUNETHEP No se ha especificado una descripción o un objeto social para esta compañía.
Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-12-21
HORIZON-EIC-2022-ACCELERATOROPEN-01: EIC Accelerator Open Scope:The EIC Accelerator supports companies (principally SMEs, including start-ups) to scale up hig...
Cerrada hace 1 año
0% 34% 100%